A small study carried out at the Human Microbiology Institute (NY, USA) and published recently in the Journal of Medical Case Reports, has revealed a potential new treatment for late-stage Alzheimer’s disease.
A team made up of Victor Tetz and George Tetz (both Human Microbiology Institute) treated a 77 year old Alzheimer’s patient with deoxyribonuclease I, a repurposed medication previously approved by the FDA for the treatment of mucus buildup in cystic fibrosis patients.
The patient had been diagnosed with dementia and behavioral disturbance secondary to late-onset Alzheimer’s disease approximately 30 months before the research team first met them and had been undergoing routine treatment without any improvement.
According to the study, improvements including recognition of family members, carrying out everyday tasks and walking, were seen in the patient following just 2 days of treatment with deoxyribonuclease I.
“Treatment with deoxyribonuclease I allowed the patient to withdraw from a terminal state and resulted in significant improvements in cognitive and behavioral function, including the ability to walk and perform everyday tasks with near independence,” explained Victor Tetz.
Hope is now that the drug will be able to be approved for treatment of dementia, Alzheimer’s and Parkinson’s diseases.
“Our results show potential for reversing the effects of a disease that dramatically impacts not only millions of patients around the world, but also their families,” commented George Tetz. “Our experimental drug has given one patient a new lease on life, and now we are continuing with our tests with the hopes of reversing the devastating effects of Alzheimer’s disease and other incurable diseases like dementia and Parkinson’s.”